Exposure to disease-modifying therapies does not increase multiple sclerosis (MS) patients’ risk of developing a severe form of COVID-19, according to a registry-based study.
However, MS patients who are older, obese, or have severe neurological impairments have a greater risk of developing a severe form of the disease.
Findings were reported in the study, “Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis,” published in the journal JAMA Neurology.
https://multiplesclerosisnewstoday.c...ts/2020/06/29/
However, MS patients who are older, obese, or have severe neurological impairments have a greater risk of developing a severe form of the disease.
Findings were reported in the study, “Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis,” published in the journal JAMA Neurology.
https://multiplesclerosisnewstoday.c...ts/2020/06/29/
Comment